Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of children globally. The clinical manifestations of AD are diverse, varying ...

Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their ...

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis The IGNITE study, which evaluated two dose strengths of ...

32.8% of rocatinlimab-treated patients achieved the co-primary endpoint of EASI 75 by week 24. 19.3% reached the other co-primary endpoint, defined as a validated IGA-AD score of 0 or 1 by week 24.

The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...

Also Read: Amgen And Kyowa Kirin’s Rocatinlimab Reduces Eczema Severity In Phase 3 Study Change from baseline in the Quantitative Myasthenia Gravis (QMG) score was also greater for patients in ...